Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B

Standard-of-care treatment for haemophilia A or B is to maintain adequate coagulation factor levels through clotting factor administration. The current study aimed to evaluate annualised bleeding rates (ABR) and treatment adherence for haemophilia A or B patients receiving standard half-life (SHL) v...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Coagul Fibrinolysis
Egile Nagusiak: Chhabra, Amit, Spurden, Dean, Fogarty, Patrick F., Tortella, Bartholomew J., Rubinstein, Emily, Harris, Simon, Pleil, Andreas M., Mellor, Jennifer, de Courcy, Jonathan, Alvir, José
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams And Wilkins 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7195855/
https://ncbi.nlm.nih.gov/pubmed/32271314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MBC.0000000000000885
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak